Introduction Of A Polynucleotide Molecule Into Or Rearrangement Of Nucleic Acid Within An Animal Cell Patents (Class 435/455)
  • Patent number: 11491231
    Abstract: This disclosure related to modular and programmable peptide-oligonucleotide chimeras comprising of peptide and oligonucleotide segments interlinked by an organic core are presented and their assembly as morphologically-tunable soft materials, for example, nanostructure compositions comprising a plurality of compounds comprising a peptide segment and an oligonucleotide segment interlinked by an organic core moiety.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: November 8, 2022
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, Northwestern University
    Inventors: Nathaniel L. Rosi, Andrea David Merg, Ryan Vachon Thaner, SonBinh T. Nguyen
  • Patent number: 11492643
    Abstract: Methods and compositions for a genetic disease are provided.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: November 8, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gregory J. Cost, Philip D. Gregory, Dmitry Guschin, Michael C. Holmes, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Lei Zhang
  • Patent number: 11492646
    Abstract: In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: November 8, 2022
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Daniel P. Dever, Rasmus O. Bak, Ayal Hendel, Waracharee Srifa, Matthew H. Porteus
  • Patent number: 11485977
    Abstract: Methods and systems for autoinduction of gene expression, without the need to add exogenous inducers. A dual genetic element system, which includes a first, high copy number genetic element comprising a first gene of interest that is under the control of an inducible promoter, and a second, low copy number genetic element comprising a gene encoding a transcriptional factor which, upon expression, regulates transcription from the inducible promoter, wherein activation of transcription from the inducible promoter does not require addition of an exogenous inducer.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: November 1, 2022
    Assignee: ADAGENE, INC.
    Inventors: Fangyong Du, Peter Peizhi Luo
  • Patent number: 11479793
    Abstract: The present invention discloses a system for targeted gene editing and related uses.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: October 25, 2022
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Shengkan Jin, Juan-Carlos Collantes
  • Patent number: 11439435
    Abstract: A stage device capable of performing piercing vibration and translational driving by using one actuator, and performing very low-speed driving in the translational driving with high accuracy. The stage device includes an X stage having a vibration actuator that includes an vibration element and a contact body, one of which is a movable body connected to an object to be driven, and drives the object to be driven in an X-axis direction, and a control section that controls driving of the vibration actuator. The control section causes two-phase AC voltages to be applied to an electromechanical energy conversion element to thereby excite predetermined vibrations in the vibration element, to drive the vibration actuator by switching between a movement mode for moving the object to be driven in the X-axis direction and a vibration mode for vibrating the object to be driven in the X-axis direction.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: September 13, 2022
    Assignee: CANON KABUSHIKI KAISHA
    Inventors: Toru Matsumoto, Hitoshi Nishitani
  • Patent number: 11441132
    Abstract: The present invention relates to improved transposase polypeptides having increased solubility. The enzyme of the invention was developed based on the Sleeping Beauty (SB) transposase. The invention provides further nucleic acids, vectors and recombinant cells encoding or containing the improved transposase, as well as a transposase system. Furthermore provided are medical and non-medical uses of the transposase of the invention for gene delivery. The invention is in particular useful as a tool for gene delivery in genetically modified cell based therapeutic approaches for treating various diseases.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: September 13, 2022
    Assignee: EUROPEAN MOLECULAR BIOLOGY LABORATORY
    Inventors: Orsolya Barabas, Irma Querques, Cecilia Ines Zuliani
  • Patent number: 11390886
    Abstract: The present invention discloses a system for targeted gene editing and related uses.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: July 19, 2022
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Shengkan Jin, Juan-Carlos Collantes
  • Patent number: 11383002
    Abstract: The present invention relates to plasma-based films and in particular to flexible plasma-based films. The invention further relates to and to methods of making and using the flexible plasma-based films. Embodiments of the invention have been particularly developed for making flexible plasma-based films useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings, as an anti-adhesive sheet to reduce or prevent development of surgery-induced adhesions, as a wound healing patch, as a wound dressing, or as a film useful in hernia repair. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: July 12, 2022
    Assignee: OCTAPHARMA AG
    Inventor: Daniel Grant Ericson
  • Patent number: 11339405
    Abstract: Disclosed herein are kits comprising transcription factors for inducing a fibroblast cell into an induced embryonic neural progenitor cell. The induced embryonic neural progenitor cell is then capable of differentiating into an astrocyte, an oligodendrocyte or a neuron. Also disclosed are the uses of the kit as a platform for selecting a drug candidate to treat neurological diseases.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: May 24, 2022
    Assignee: ACADEMIA SINICA
    Inventors: Hung-Chih Kuo, Ching-Yu Chuang, Chan-Hsien Yeh
  • Patent number: 11319555
    Abstract: Disclosed herein are compositions and methods for cell therapy comprising an engineered cell. The present invention is directed to a composition for treating a subject having or suspected of having a disease, the composition comprising a modified cell comprising a modified endogenous gene, wherein an endogenous gene or fragment thereof is replaced with a transgene using a CRISPR/Cas9 system to generate the modified endogenous gene, the modified cell having an altered response to a cell signal or stimulus.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: May 3, 2022
    Assignee: Duke University
    Inventors: Farshid Guilak, Jonathan M. Brunger, Charles A. Gersbach
  • Patent number: 11311568
    Abstract: The object of the present invention is to find a pharmaceutical having strong cancer therapeutic effect. The present invention provides a pharmaceutical composition for cancer therapy comprising a transcription or processing product of a gene encoding a miRNA, wherein said miRNA is one or more miRNAs selected from the group consisting of miR-3140, miR-137, miR-631, and miR-657, pharmaceutical composition.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: April 26, 2022
    Assignee: PURMX THERAPEUTICS, INC.
    Inventors: Hidetoshi Tahara, Masaki Kinehara, Yuki Yamamoto
  • Patent number: 11306287
    Abstract: Compositions and methods of the invention are directed to the formation and use of teratoma-derived skeletal muscle stem cells. In one embodiment, the teratoma-derived skeletal muscle stem cells improve muscle contractile force (definition “functional”) when administered to a patient in need thereof.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: April 19, 2022
    Assignee: Regents of the University of Minnesota
    Inventors: Michael Kyba, Sun Kin Sunny Chan, Robert W. Arpke
  • Patent number: 11286476
    Abstract: Methods of substantially retaining or otherwise preserving the biological activity of a dsRNA, present in a cell, to post-transcriptionally silence the expression of a gene in a target organism, comprising the step of adding to the cell composition a compound having the function of a protein—or amine—cross linking agent and/or an acid, and compositions comprising the cells comprising dsRNA, and protein cross linking agents and/or acids, as well as the use of the cross linking agents and/or acids in the method.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: March 29, 2022
    Assignees: SYNGENTA PARTICIPATIONS AG, Devgen NV
    Inventors: Pascale Feldmann, Jeffrey David Fowler, Nema Devi Jhurry, Isabelle Maillet, Marta Omedes Pujol
  • Patent number: 11248238
    Abstract: Provided herein are methods for transducing a plurality of cells in a composition of cells, such as a population of lymphocytes, containing viral particles. In some aspects, provided methods and reagents for the transduction of cell populations involve binding of agents to a molecule on the surface of the cells. In some cases, the reagents are multimerization reagents and the one or more agents are multimerized by reversibly binding to the reagent. In some aspects, the multimerized agent can provide for transduction and/or expansion or proliferation or other stimulation of a population of cells, and then such agents can be removed by disruption of the reversible bond. Also provided are compositions, apparatus and methods of use thereof.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: February 15, 2022
    Assignee: Juno Therapeutics GmbH
    Inventors: Keenan Bashour, Semih U. Tareen
  • Patent number: 11242541
    Abstract: Provided is a method for inducing a skeletal muscle cell including a step of introducing MyoD family gene or an expression product thereof and Myc family gene or an expression product thereof into a somatic cell of a mammal.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: February 8, 2022
    Assignee: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
    Inventors: Junko Wakao, Tsunao Kishida, Tatsuro Tajiri, Osam Mazda
  • Patent number: 11229721
    Abstract: The invention includes chitosan nanofibers having enhanced structural integrity, compositions comprising such chitosan nanofibers, and related methods of use. In a particular aspect, electrospun chitosan nanofibers can be reversibly acylated to enhance structural integrity and promote healing and the formation of tissues in a subject. In another aspect, electrospun chitosan nanofibers comprising at least a portion of the amino groups protected, such as through N-tert-butoxycarbonyl groups, demonstrate enhanced structural integrity and promote healing and the formation of tissues in a subject. The invention also includes compositions and methods for producing a modified chitosan material having anti-inflammatory and pro-healing characteristics and methods of using the modified chitosan materials in a film, a gel, a membrane, microfibers, nanofibers, nano- or micro-particles/spheres and/or sponges. In some aspects, microspheres and methods of producing microspheres comprising modified chitosan are included.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: January 25, 2022
    Assignee: THE UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION
    Inventors: Joel D. Bumgardner, Chaoxi Wu, Hengjie Su, Tomoko Fujiwara, Daniel G. Abebe, Kwei-Yu Liu, Gregory McGraw, Carlos Lee Bumgardner
  • Patent number: 11198127
    Abstract: Embodiments of the present disclosure can include a method for convective intracellular delivery including providing cells and molecules to a microchannel having compressive surfaces, wherein the compressive surfaces define compression gaps having a height of from 20 and 80% of the average cell diameter; and a plurality of relaxation spaces disposed between the compressive surfaces; flowing the cell medium through the microchannel, wherein as the cell medium flows through the microchannel, the plurality of cells undergo a convective intracellular delivery process comprising: compressing the plurality of cells, wherein the compressing causes the plurality of cells to undergo a loss in intracellular volume (Vloss); and passing the plurality of cells to a first relaxation space, wherein the plurality of cells undergo a gain in volume (Vgain) and absorb a portion of the plurality of molecules.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: December 14, 2021
    Assignee: Georgia Tech Research Corporation
    Inventors: Todd Sulchek, Alexander Alexeev, Anna Liu
  • Patent number: 11193108
    Abstract: Provided is an isolated population of human pluripotent stem cells comprising at least 50% human pluripotent stem cells characterized by an OCT4+/TRA1-60?/TRA1-81?/SSEA1+/SSEA4? expression signature, and novel methods of generating and maintaining same in a pluripotent, undifferentiated state a suspension culture devoid of cell clumps. Also provided are novel culture media, cell cultures and methods for culturing pluripotent stem cells in a suspension culture or a two-dimensional culture system while maintaining the cells in a proliferative, pluripotent and undifferentiated state. The novel culture media comprise interleukin 11 (IL11) and Ciliary Neurotrophic Factor (CNTF); bFGF at a concentration of at least 50 ng/ml and an IL6RIL6 chimera; or an animal contaminant-free serum replacement and an IL6RIL6 chimera. Also provided are methods for generating lineage-specific cells from the pluripotent stem cells.
    Type: Grant
    Filed: August 5, 2018
    Date of Patent: December 7, 2021
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Michal Amit, Joseph Itskovitz-Eldor
  • Patent number: 11186828
    Abstract: The present disclosure relates to a medium composition for r25/eprogramming induced pluripotent stem cells, containing an Ecklonia cava extract. Also, the present disclosure relates to a method for manufacturing induced pluripotent stem cells by using the medium composition. When the medium composition according to the present disclosure is used, induced pluripotent stem cells can be efficiently produced using adipose-derived mesenchymal stem cells safely and easily. The manufactured pluripotent stem cells are differentiable into various cells, and thus can be favorably used as a cell therapeutic agent.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: November 30, 2021
    Assignee: BBHC CO., LTD.
    Inventors: Sang Yeon Lee, Won Ju Jung, Ho Bin Kim, Min Sun Oh, Kye Ho Lee
  • Patent number: 11167044
    Abstract: Methods for producing new neurons in the brain in vivo are provided according to aspects of the present invention which include introducing NeuroD1 into a glial cell, particularly into a reactive astrocyte or NG2 cell, thereby “converting” the reactive glial cell to a neuron. Methods of producing a neuronal phenotype in a glial cell are provided according to aspects of the present invention which include expressing exogenous NeuroD1 in the glial cell, wherein expressing exogenous NeuroD1 includes delivering an expression vector, such as a viral expression vector, including a nucleic acid encoding the exogenous NeuroD1 to the glial cell.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: November 9, 2021
    Assignee: The Penn State Research Foundation
    Inventors: Gong Chen, Lei Zhang, Zheng Wu, Yuchen Chen, Fan Wang, Ziyuan Guo
  • Patent number: 11149278
    Abstract: The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3?-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention further relates to a vector comprising the artificial nucleic acid molecule comprising an open reading frame and a 3?-UTR comprising at least one poly(A) sequence or a polyadenylation signal, to a cell comprising the artificial nucleic acid molecule or the vector, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3?-UTR for a method for increasing protein production from an artificial nucleic acid molecule.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: October 19, 2021
    Assignee: CureVac AG
    Inventors: Andreas Thess, Thomas Schlake, Stefanie Grund
  • Patent number: 11136597
    Abstract: Compositions and methods for enhancing targeted gene editing and methods of use thereof are disclosed. In the most preferred embodiments, gene editing is carried out utilizing a gene editing composition such as triplex-forming oligonucleotides, CRISPR, zinc finger nucleases, TALENS, or others, in combination with a gene modification potentiating agent such as stem cell factor (SCF), a CHK1 or ATR inhibitor, or a combination thereof. A particular preferred gene editing composition is triplex-forming peptide nucleic acids (PNAs) substituted at the ? position for increased DNA binding affinity. Nanoparticle compositions for intracellular delivery of the gene editing composition are also provided and particular advantageous for use with in vivo applications.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: October 5, 2021
    Assignees: Yale University, Carnegie Mellon University
    Inventors: W. Mark Saltzman, Peter Glazer, Raman Bahal, Nicole Ali McNeer, Danith H. Ly, Elias Quijano
  • Patent number: 11102961
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Lymphocyte activation gene 3 (Lag3). The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Lag3 locus so that the non-human animals express a Lag3 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: August 31, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Alexander O. Mujica, Elena Burova, Andrew J. Murphy
  • Patent number: 11078494
    Abstract: The invention provides a method for generating a transgenic eukaryotic cell population having a modified human Rosa26 locus, which method includes introducing a functional DNA sequence into the human Rosa26 locus of starting eukaryotic cells. Also provided are targeting vectors useful in the method, as well as a cell population and a transgenic non-human animal comprising a modified human Rosa26 locus. Finally, the invention provides an isolated DNA sequence corresponding to the human Rosa26 locus.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: August 3, 2021
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Gordon Keller, Stefan Irion, Herve Luche, Paul Gadue, Hans J. Fehling
  • Patent number: 11045584
    Abstract: A process for producing a bone construct, including the steps of providing a perfusion bioreactor having an inlet and an outlet; providing the perfusion bioreactor with a seeded scaffold comprising a porous scaffold seeded with mesenchymal stem cells; continuously perfusing the seeded scaffold with an osteogenic induction (differentiation) media; measuring dissolved oxygen content of the osteogenic induction media at the inlet and at the outlet to determine an oxygen uptake rate (OUR) for the seeded scaffold; measuring glucose content of the osteogenic induction media to determine a glucose consumption rate (GCR) for the seeded scaffold; and removing the seeded scaffold from the perfusion reactor as a bone construct after the ratio of the OUR to the GCR (OUR/GCR) has been determined to exceed a predetermined threshold OUR/GCR value.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: June 29, 2021
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Vassilios Sikavitsas, Aaron D. Simmons
  • Patent number: 11030531
    Abstract: The invention provides, inter alia, recombinase-based systems that provide for integrated logic and memory in living cells such as mammalian cells. The nucleic acid cassettes, switches, and systems described herein allow for control of gene expression or gene regulation. The invention also provides nucleic acid-based switches for adopted T-cell therapy.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: June 8, 2021
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Wilson W. Wong, Benjamin Harris Weinberg
  • Patent number: 11015204
    Abstract: This invention provides expressible polynucleotides, which can express a target protein or polypeptide. Synthetic mRNA constructs for producing a protein or polypeptide can contain one or more 5? UTRs, where a 5? UTR may be expressed by a gene of a plant. In some embodiments, a 5? UTR may be expressed by a gene of a member of Arabidopsis genus. The synthetic mRNA constructs can be used as pharmaceutical agents for expressing a target protein or polypeptide in vivo.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: May 25, 2021
    Assignee: Arcturus Therapeutics, Inc.
    Inventors: Pattraranee Limphong, Carlos G. Perez-Garcia, Kiyoshi Tachikawa, Padmanabh Chivukula, Arisa Cale, Angel I-Jou Leu, Jared Davis
  • Patent number: 11001809
    Abstract: Disclosed herein are methods of generating induced pluripotent stem cells. The method involves providing a quantity of somatic or non-embryonic cells, contacting the contacting the somatic or non-embryonic cells with a quantity of one or more reprogramming factors and one or more RNA molecules, and culturing the somatic or non-embryonic cells for a period of time sufficient to generate at least one induced pluripotent stem cell. Various reprogramming factors and RNA molecules for use in the methods are disclosed herein. Also disclosed are cell lines and pharmaceutical compositions generated by use of the methods.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: May 11, 2021
    Assignee: The McLean Hospital Corporation
    Inventors: Kwang-Soo Kim, Young Cha
  • Patent number: 10975136
    Abstract: The present invention relates to the field of genetic engineering, in particular, to a transposon-based transfection kit suitable for transfection of primary cells, such as T cells, comprising mRNA encoding a transposase, or reagents for generating mRNA encoding said transposase, as well as minicircle DNA comprising the transposon. The invention also relates to a nucleic acid, preferably, a DNA minicircle, comprising a transposon, wherein the transposon encodes a protein and at least one miRNA, wherein the sequences encoding the miRNA are located in an intron and expression of the protein and the miRNA is regulated by the same promoter. The invention also provides a population of cells obtainable with the method of the invention. Methods of transfection are also provided, as well as medical use, e.g. in immunotherapy, in particular, in adoptive T cell therapy or T cell receptor (TCR) or chimeric antigen receptor (CAR) gene therapy.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: April 13, 2021
    Assignee: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
    Inventors: Wolfgang Uckert, Mario Bunse, Julian Clauss, Zsuzsanna Izsvák
  • Patent number: 10959413
    Abstract: A method of modulating some or all copies of a gene in a cell is provided including introducing into a cell one or more ribonucleic acid (RNA) sequences that comprise a portion that is complementary to all or a portion of each of the one or more target nucleic acid sequences, and a nucleic acid sequence that encodes a Cas protein and maintaining the cells under conditions in which the Cas protein is expressed and the Cas protein binds and modulates the one or more target nucleic acid sequences in the cell.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: March 30, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Luhan Yang, Marc Guell
  • Patent number: 10923490
    Abstract: A semiconductor memory device includes a semiconductor substrate, a first insulating film provided above the semiconductor substrate, a first conductive film provided above the first insulating film, a plurality of first electrode films provided above the first conductive film and stacked to be separated from each other, a semiconductor member extending in a stacking direction of the plurality of first electrode films, and a charge storage member provided between the semiconductor member and one of the plurality of first electrode films. The first conductive film includes a main portion disposed at least below the plurality of first electrode films, and a fine line portion extending from the main portion toward an end surface side of the semiconductor substrate. A width of the fine line portion is narrower than a width of the main portion.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: February 16, 2021
    Assignee: Toshiba Memory Corporation
    Inventors: Kotaro Fujii, Jun Fujiki, Shinya Arai
  • Patent number: 10888589
    Abstract: Methods and compositions for modifying stem cells using one or more ZFPs are disclosed. Such methods and compositions are useful for facilitating processes such as, for example, dedifferentiating cells, differentiating stem cells into the desired phenotype, propagating stem cells and/or facilitating cloning.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: January 12, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Alan P. Wolffe, Michael Moore, Timothy Farries, Trevor Collingwood, Fyodor Urnov
  • Patent number: 10889834
    Abstract: Disclosed herein are methods and compositions for enhancing insertion of transgene sequences encoding proteins that is aberrantly expressed in disease or disorder such as a lysosomal storage disease or a hemophilia by administering one or more topoisomerases inhibitors, one or more stabilizers of R loop formation or inhibitors of R-loop repair and/or one or more up-regulators of the TC-NER pathway to the target cell.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: January 12, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gregory J. Cost, Thomas Wechsler
  • Patent number: 10876126
    Abstract: This invention provides methods for producing a non-natural hybrid seed. Also disclosed are specific miRNAs and miRNA recognition sites useful for conferring inducible sterility on a crop plant, and recombinant DNA construct including such exogenous miRNA recognition sites.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: December 29, 2020
    Assignee: Monsanto Technology LLC
    Inventors: Edwards Allen, Larry A. Gilbertson, James K. Roberts, Nancy M. Houmard, Shihshieh Huang, Sergey Ivashuta
  • Patent number: 10858357
    Abstract: The present invention relates to highly soluble, non-fluorescent and photostable myosin inhibitors; especially, for in vivo inhibition of the ATPase activity of neuronal non-muscle myosin 2 of formula (II): wherein Q1, Q2, Q3, Q4, R1, R2, R4 and R5 are as defined in claim 1. The invention also relates to pharmaceutical compositions or medicaments comprising the compounds of the invention and processes for manufacturing these compounds and their intermediates.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: December 8, 2020
    Assignees: PARIS SCIENCES ET LETTRES-QUARTIER LATIN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), PRINTNET LTD.
    Inventors: Zsolt Lenkei, András Málnási Csizmadia, Miklós Képiró, Boglárka Várkuti
  • Patent number: 10849981
    Abstract: The presently described technology provides methods of treating a patient having moderate to severe pain, narcotic or opioid abuse or narcotic or opioid withdrawal. The presently described methods are carried out by comprising administering to the patient a pharmaceutically effective amount of a composition comprising acetaminophen and benzoate-hydrocodone hydrochloride. The composition has reduced side effects when compared with unconjugated hydrocodone.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: December 1, 2020
    Assignee: KemPham, Inc.
    Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
  • Patent number: 10793620
    Abstract: The invention refers to a non-therapeutic method for producing antigen-specific B cells by using the adoptive cell transfer of primed B cells, especially of spleen cells including B cells of a previously immunized non-human animal and by administering an antigen of interest to a naïve non-human animal.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: October 6, 2020
    Assignee: BIOGENES GMBH
    Inventor: Detlef Schmechel
  • Patent number: 10787523
    Abstract: Various embodiments disclosed relate to a nanoparticle-protein complex for intracellular protein delivery. In various embodiments, the present invention provides a nanoparticle-protein complex including a nanoparticle including an amine-containing ligand. The nanoparticle-protein complex also includes a protein comprising a carboxylic acid-containing tag.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: September 29, 2020
    Assignee: University of Massachusetts
    Inventors: Vincent M. Rotello, Rubul Mout
  • Patent number: 10787662
    Abstract: Provided herein are methods and compositions to make guide nucleic acids (gNAs), nucleic acids encoding gNAs, collections of gNAs, and nucleic acids encoding for a collection of gNAs from any source nucleic acid. Also provided herein are methods and compositions to use the resulting gNAs, nucleic acids encoding gNAs, collections of gNAs, and nucleic acids encoding for a collection of gNAs in a variety of applications.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: September 29, 2020
    Assignee: ARC BIO, LLC
    Inventor: Stephane B. Gourguechon
  • Patent number: 10782304
    Abstract: The present invention relates to methods and kits for detection protein-protein interactions.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: September 22, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PAUL SABATIER TOULOUSE III
    Inventors: Stéphanie Cabantous, Faten Koraïchi, Gilles Favre
  • Patent number: 10765758
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: September 8, 2020
    Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz
  • Patent number: 10745692
    Abstract: An object of the present invention is to provide a method of producing a peptide containing a charged non-proteinogenic amino acid in a cell-free translation system, and the like. The present invention provides a method of producing a peptide containing a charged non-proteinogenic amino acid. It includes a step of expressing a peptide in a cell-free translation system including (i) at least one tRNA to which a non-proteinogenic amino acid having a protecting-group-introduced charged group has been bound and (ii) a nucleic acid that encodes the peptide and contains at least one codon corresponding to an anticodon of the tRNA; and a step of removing the protecting group of the non-proteinogenic amino acid residue contained in the peptide.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: August 18, 2020
    Assignees: The University of Tokyo, PeptiDream Inc.
    Inventors: Hiroshi Murakami, Takashi Kawakami, Patrick Reid, Toru Sasaki
  • Patent number: 10745716
    Abstract: The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: August 18, 2020
    Assignee: Sigma-Aldrich Co. LLC
    Inventors: Fuqiang Chen, Gregory D. Davis
  • Patent number: 10731181
    Abstract: The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: August 4, 2020
    Assignee: Sigma, Aldrich Co. LLC
    Inventors: Fuqiang Chen, Gregory D. Davis
  • Patent number: 10724005
    Abstract: Disclosed herein are methods of producing chondrocytes from pluripotent stem cells. The invention further provides methods of regenerating cartilaginous tissue.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: July 28, 2020
    Assignee: SCRIPPS HEALTH
    Inventors: Darryl D. D'Lima, Tsaiwei Olee, Clifford W. Colwell
  • Patent number: 10724010
    Abstract: The present disclosure relates to recombinantly engineered cells that contain a chlorite dismutase polypeptide and methods for culturing such cells in a culture medium containing chlorite in an amount sufficient to reduce the growth rate or kill contaminating microorganisms without killing the recombinantly engineered cells. Also provided are methods for the production of a fermentation product using the recombinantly engineered cells.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: July 28, 2020
    Assignee: The Regents of the Uniiversity of California
    Inventor: John D. Coates
  • Patent number: 10709761
    Abstract: The present disclosure is directed to methods and compositions for inhibiting a cancer cell using nucleic acid sequences encoding elephant p53 or elephant p53 amino acid sequences.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: July 14, 2020
    Assignees: UNIVERSITY OF UTAH RESEARCH FOUNDATION, TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
    Inventors: Joshua Schiffman, Avi Schroeder, Lisa Abegglen
  • Patent number: 10683490
    Abstract: Methods of making mutant Cas9 proteins are described.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: June 16, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Alejandro Chavez, Frank J. Poelwijk, George M. Church
  • Patent number: 10654918
    Abstract: Anti-cytokine therapy has revolutionized immunological disease treatment, but is not always effective and subject to treatment resistance as the cytokine cascade is highly redundant and multiple cytokines are involved in inflammation. Targeting a critical common regulator of inflammatory effectors is desirable. Lipopolysaccharide (LPS)-responsive beige-like anchor (LRBA) is a master regulator of multiple genes important for inflammation. Subcellular localization shows that LRBA translocated to the nucleus upon LPS stimulation and colocalized with multiple proteins associated with the endosome membrane system, indicating a critical role in membrane/vesicle trafficking essential for deposition, secretion and signal transduction of immune effectors.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: May 19, 2020
    Assignee: University of South Florida
    Inventors: Jia-Wang Wang, Richard F. Lockey